ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 451 for:    COPD | Recruiting, Not yet recruiting, Available Studies | "Pulmonary Disease, Chronic Obstructive"

Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03436511
Recruitment Status : Recruiting
First Posted : February 16, 2018
Last Update Posted : August 13, 2018
Sponsor:
Collaborator:
Oblikue Consulting
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This observational study is designed to more specifically describe the burden of the disease and the use of healthcare resources of subjects with eosinophilic COPD that may be eligible in the future for a biologic treatment. Subjects who attend a routine follow-up visit and fulfill the inclusion/exclusion criteria defined provide a signed informed consent will be invited by the investigator to participate in this study. Subjects will be recruited in hospital Pulmonology Services across Spain. It is planned to include approximately 20 centers. To select the final participating centers, a feasibility study has been carried out in approximately 50 potential participating centers. It has been estimated that each investigator will include 18 subjects during the 4-month inclusion period. Total 354 subjects will be required: 250 subjects with an eosinophil level >=150 cells per microliter and 104 subjects with an eosinophil level <150 cells per microliter. The study inclusion period will be 4 months (expected to be from November 2017 to March 2018) and the retrospective data collection period will be 12 months prior to the inclusion visit.

Condition or disease
Pulmonary Disease, Chronic Obstructive

Study Type : Observational
Estimated Enrollment : 354 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Burden of Disease Among Patients With Eosinophilic COPD in Spain: Multicentre Observational Study
Actual Study Start Date : December 5, 2017
Estimated Primary Completion Date : October 31, 2018
Estimated Study Completion Date : October 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD

Group/Cohort
Subjects with COPD
Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.



Primary Outcome Measures :
  1. Number of subjects requiring COPD maintenance treatment and rescue medication [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects currently exposed to inhaled triple maintenance therapy, defined as at least one overlapping prescription of an inhaled corticosteroid (ICS) with a long-acting beta2-agonist (LABA) and with a long-acting muscarinic antagonist (LAMA) in 2 or 3 inhaler devices, without more than 30 days of separation between prescriptions along with rescue medication use will be analyzed.

  2. Number of subjects with moderate and severe exacerbations [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects who have experienced >=2 moderate exacerbations or >=1 severe exacerbation in the 12 months prior to the inclusion visit. Moderate exacerbation is defined as an exacerbation requiring antibiotics and/or oral corticosteroids or requiring an emergency visit <24 hours (without hospitalization). Severe exacerbation is defined as an exacerbation requiring hospitalization.

  3. Number of subjects with COPD-related scheduled and unscheduled primary and secondary care visits [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects with COPD-related scheduled and unscheduled primary and secondary care visits will be analyzed.

  4. Number of subjects with COPD-related emergency visits to primary care and hospital [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects with COPD-related emergency visits to primary care and hospital will be analyzed.

  5. Number of subjects with COPD-related hospitalizations [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects with COPD-related hospitalizations will be analyzed.

  6. Number of days of hospitalizations [ Time Frame: 12 months prior to the inclusion visit ]
    The number of days of hospitalization for subjects will be analyzed.

  7. Number of subjects with COPD-related complementary tests [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects with COPD-related complementary tests will be analyzed.

  8. Number of subjects with COPD-related days-off work [ Time Frame: 12 months prior to the inclusion visit ]
    Subjects with COPD-related days-off work will be analyzed.


Secondary Outcome Measures :
  1. Subjects age as a measure of sociodemographic characteristics [ Time Frame: 4 months (inclusion period) ]
    Age will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study. A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.

  2. Number of subjects with different gender [ Time Frame: 4 months (inclusion period) ]
    Gender will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study. A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.

  3. Number of subjects with different sociodemographic variables [ Time Frame: 4 months (inclusion period) ]
    Subjects with different educational level, employment status, monthly net income will be recorded for descriptive analysis of the sociodemographic characteristics of the subjects participating in the study A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.

  4. Number of subjects with abnormal clinical variables [ Time Frame: 4 months (inclusion period) ]
    Clinical variables comprising weight, height, body mass index (self-calculated), smoking history, Charlson comorbidity index, diagnosis of asthma will be assessed for abnormalities. A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.

  5. Number of subjects with abnormal COPD related variables [ Time Frame: 12 months prior to the inclusion visit ]
    COPD variables comprising COPD diagnosis date, pulmonary function with bronchodilator test, modified Medical Research Council (mMRC) dyspnea scale, clinical phenotypes according to Spanish COPD Clinical Guidelines (GesEPOC) criteria will be assessed for abnormalities. A threshold of >=150 cells/microliter will be considered to determine a high level of eosinophil's, so only subjects meeting this criterion will be included in the analysis.

  6. Number of subjects with abnormal blood cell count [ Time Frame: 12 months prior to the inclusion visit ]
    Peripheral blood eosinophil count, peripheral blood neutrophil count, peripheral blood leukocyte count, fibrinogen and red cell distribution width will be assessed for abnormalities.

  7. COPD Assessment Test (CAT) score as a measure of Health Related Quality of Life (HRQoL) [ Time Frame: 4 months (inclusion period) ]
    The CAT questionnaire is a COPD-specific questionnaire that measures the impact of the disease on HRQoL and allows symptoms to be described. It consists of 8 items, which yield a score range from 0 to 40, 0 representing the lowest impact on HRQoL and 40 the maximum impact.

  8. EuroQOL five dimensions five level (EQ-5D-5L) score as a measure of HRQoL [ Time Frame: 4 months (inclusion period) ]
    The EQ-5D-5L is a preference-based generic HRQoL questionnaire, consisting on five health dimensions (mobility, personal care, daily activities, pain/discomfort and anxiety/depression), divided in five levels of severity (no problems, slight problems, moderate problems, severe problems and extreme problems). It included also a visual analogue scale (VAS) in which respondents are asked to evaluate their overall health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects who attend a routine follow-up visit and who fulfill inclusion/exclusion criteria will be invited by the investigator to participate in the study. The study inclusion period will be four months (from November 2017 to March 2018) and the retrospective data collection period will be 12 months prior to the inclusion visit.
Criteria

Inclusion Criteria:

  • Subjects of both sexes aged >=40 years.
  • Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record.
  • Subjects with a history of smoking (current or past) >=10 pack-years.
  • Subjects who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit. If the subject has several eosinophil test recorded in this period, the one closest to the inclusion visit determined in the stable phase should be selected; if it is not available, the record closest to the inclusion visit will be selected, even if it has been determined during an exacerbation. If no records are available, the subject will be invited to perform the test at the inclusion visit.
  • Subjects currently exposed to inhaled triple maintenance therapy, defined as at least one overlapping prescription of an ICS with a LABA and with a LAMA in 2 or 3 inhaler devices, without more than 30 days of separation between prescriptions.
  • Subjects who have experienced >=2 moderate exacerbations or >=1 severe exacerbation in the 12 months prior to the inclusion visit. Moderate exacerbation is defined as an exacerbation requiring antibiotics and/or oral corticosteroids or requiring an emergency visit <24 hours (without hospitalization). Severe exacerbation is defined as an exacerbation requiring hospitalization.
  • Subjects who consent to participate in the study by signing the subjects written informed consent form.

Exclusion Criteria:

  • Subjects without a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit and who refuse to perform the test during the inclusion visit.
  • Subjects treated with oral corticosteroids continuously during the 12 months prior to the inclusion visit.
  • Subjects with a diagnosis of Churg-Strauss disease, hypereosinophilic syndrome, allergic bronchopulmonary aspergillosis or other conditions that result in increased eosinophil levels independently of COPD.
  • Subjects with oncologic disease undergoing treatment or with advanced oncologic disease (without possibility of remission), terminal subjects and/or subjects receiving palliative care.
  • Cognitively impaired subjects who are not able to understand or complete the informed consent and HRQoL questionnaires.
  • Subjects who have participated in an interventional clinical trial during the 12 months prior to the inclusion visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03436511


Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

Locations
Spain
GSK Investigational Site Recruiting
Barcelona, Spain, 08036
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
GSK Investigational Site Recruiting
Madrid, Spain, 28040
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
GSK Investigational Site Recruiting
Madrid, Spain, 28046
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
GSK Investigational Site Recruiting
Valencia, Spain, 46017
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Sponsors and Collaborators
GlaxoSmithKline
Oblikue Consulting
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03436511     History of Changes
Other Study ID Numbers: 206555
First Posted: February 16, 2018    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Health resource utilization
Eosinophilic COPD
Mepolizumab

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes